Top Banner
1 the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak
55

1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

Jan 02, 2016

Download

Documents

Katrina Patrick
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

1

Scalable Technology for the Extraction of Pharmaceutics

Group #5

Christine Spina

Jeremy Katusak

Page 2: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

2

• Introduction—Christine

• Application case studies

• What comes next?—Jeremy

Page 3: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

3Introduction

• What is CCC?

• A brief history

• Technology Readiness Levels

Page 4: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

4What is CCC?

• Counter-current chromatography• Liquid-Liquid extraction• Liquid-Liquid chromatography

• Lower downstream processing costs

Page 5: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

5What is CCC?

• Advantages• Quick

Page 6: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

6What is CCC?

• Advantages• Quick

• Inexpensive

Page 7: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

7What is CCC?

• Advantages• Quick

• Inexpensive

• Gentle and versatile

Page 8: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

8What is CCC?

• Advantages• Quick

• Inexpensive

• Gentle and versatile

• Range

Page 9: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

9Introduction

• What is CCC?

• A brief history

• Technology Readiness Levels

Page 10: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

10A brief history

• CCC first introduced in 1966• “I” type centrifuges

• 1980s• “J” type centrifuges

Page 11: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

11A brief history

• Brunel Institute for Bioengineering (BIB)• Brunel CCC prototype

Page 12: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

12A brief history

• EPSRC-IMI programme• 4.6L Maxi CCC prototype

Page 13: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

13A brief history

• EPSRC-IMI programme• Further scale-up of the 18L

Page 14: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

14A brief history

• EPSRC-IMI programme• Scale down: Mini CCC prototype

(5.4 or 17.8 mL)

Page 15: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

15Introduction

• What is CCC?

• A brief history

• Technology Readiness Levels

Page 16: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

16Technology Readiness Levels

• Brunnel:• TRL4

• Dynamic Extractions:• TRL5-7

• Current TSP-STEP:• TRL 8

Page 17: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

17

• Introduction—Christine

• Application case studies

• What comes next?—Jeremy

Page 18: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

18Application Case Studies

• Separation of syn/anti isomers

• Isolation of intermediate

• Separation of isomers

• Isolation of a peroxy-substituted compound

Page 19: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

19Separation of syn/anti isomers

High-Performance Liquid Chromatography (HPLC) of crude containing 32% of target anti isomer

Page 20: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

20Separation of syn/anti isomers

HPLC of crude containing 32% of target anti isomer

Page 21: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

21Separation of syn/anti isomers

HPLC of crude containing 68% of target syn isomer

Page 22: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

22Separation of syn/anti isomers

CCC chromatogram: isolation of anti-isomer >98%

Page 23: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

23Application Case Studies

• Separation of syn/anti isomers

• Isolation of intermediate

• Separation of isomers

• Isolation of a peroxy-substituted compound

Page 24: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

24Isolation of intermediate

HPLC of mixturecontaining 64% of starting material

Page 25: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

25Isolation of intermediate

HPLC of mixturecontaining 64% of starting material

Page 26: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

26Isolation of intermediate

HPLC of recovered target

Page 27: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

27Application Case Studies

• Separation of syn/anti isomers

• Isolation of intermediate

• Separation of isomers

• Isolation of a peroxy-substituted compound

Page 28: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

28Separation of isomers

High-Performance Liquid Chromatography (HPLC) of crude containing 74% of target

Page 29: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

29Separation of isomers

HPLC of crude containing 74% of target

Page 30: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

30Separation of isomers

HPLC of crude containing 74% of target

Page 31: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

31Separation of isomers

HPLC of purified fraction.

Page 32: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

32Separation of isomers

HPLC of purified fraction.

98% purity.

Page 33: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

33Separation of isomers

HPLC of purified fraction.

98% purity.

95% recovery

Page 34: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

34Application Case Studies

• Separation of syn/anti isomers

• Isolation of intermediate

• Separation of isomers• Isolation of a peroxy-substituted compound

Page 35: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

35

Isolation of a peroxy-substitued compound

Crude: 87% Purity

Page 36: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

36

Isolation of a peroxy-substitued compound

Crude: 87% Purity

Issue: Bromo-impurity

Page 37: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

37

Isolation of a peroxy-substitued compound

Crude: 87% Purity

Issue: Bromo-impurity

Page 38: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

38

Isolation of a peroxy-substitued compound

Crude: 87% Purity

Issue: Bromo-impurity

Goals: >95% purity

Page 39: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

39

Isolation of a peroxy-substitued compound

Crude: 87% Purity

Issue: Bromo-impurity

Goals: >95% purity AND

no bromo-analogue

Page 40: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

40

Isolation of a peroxy-substitued compound

Refined: 95.2% purity

59% recovered

Page 41: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

41

• Introduction—Christine

• Application case studies

• What comes next?—Jeremy

Page 42: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

42What comes next?

• Challenges

• Future goals

Page 43: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

43

Challenges

• Solid phase preparative chromatography

Page 44: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

44

Challenges

• Solid phase preparative chromatography• Currently the technique of choice• Well established

Page 45: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

45

Challenges

• Solid phase preparative chromatography• Currently the technique of choice• Well established

• Understanding the considerations

Page 46: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

46

Challenges

• Solid phase preparative chromatography• Currently the technique of choice• Well established

• Understanding the considerations

• Manufacturing scale• Chromatographic processes to isolate?!• Effective control

Page 47: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

47

Challenges

• Solid phase preparative chromatography• Currently the technique of choice• Well established

• Understanding the considerations

• Manufacturing scale• Chromatographic processes to isolate?!• Effective control

• Regulations

Page 48: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

48What comes next?

• Challenges

• Future goals

Page 49: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

49

Future goals

• One year down, two to go!

Page 50: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

50

Future goals

• One year down, two to go!

• Rapid method development

Page 51: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

51

Future goals

• One year down, two to go!

• Rapid method development

• Automation

Page 52: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

52

Future goals

• One year down, two to go!

• Rapid method development

• Automation

• Continuous processing

Page 53: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

53

Future goals

• One year down, two to go!

• Rapid method development

• Automation

• Continuous processing

• Reliability and robustness

Page 54: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

54

References• Article:

Ian Sutherland, Svetlana Ignatova, Peter Hewitson, et. all, Scalable Technology for the Extraction of Pharmaceutics (STEP): The transition from academic knowhow to industrial reality, Journal of Chromatography A, Volume 1218, Issue 36, 9 September 2011, Pages 6114-6121. (http://www.sciencedirect.com/science/article/pii/S002196731100046X)

• Images

Ted: http://www.tempestfreerunning.com/ted-the-movie-tempest-makes-cameo

Money: http://www.123rf.com/photo_1767615_pennies-on-the-dollar--one-dollar-bill-with-small-stacks-of-pennies-on-top-on-a-white-background.html

stopwatch: http://technologytom.com/html/reaction_time.html 

measuring cups http://www.gourmetsleuth.com/images/dry_measuring_cups.jpg

I type: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815076/

J type: http://ars.els-cdn.com/content/image/1-s2.0-S0021967304023374-gr1.gif

Page 55: 1 Scalable Technology for the Extraction of Pharmaceutics Group #5 Christine Spina Jeremy Katusak.

55

Questions?